straitstimes.com·3 min read·medium
US FDA approves first mRNA flu shot from Moderna
✦AI Summary
The US FDA has granted approval for Moderna's mRNA-based flu vaccine, mFlusiva, for adults aged 50 and older. This marks the first time an mRNA vaccine has been approved for seasonal influenza, though analysts do not expect significant revenue until 2027.
Moderna has agreed to run an additional study and submit more data in adults 65 and older to confirm the vaccine’s benefit in that age group.
healthsciencebusiness
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in